市場調査レポート

商品コード

1631496

体外診断用酵素の市場規模、シェア、動向分析レポート：酵素別、疾患別、技術別、最終用途別、地域別、セグメント別予測、2025年～2030年

In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme (Polymerase & Transcriptase, Proteases), By Disease (Infectious Disease, Diabetes), By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030

出版日: 2024年12月17日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF (Single User License)

USD 5,950 891,548円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。PDFの印刷もできません。

Printable PDF (5-User License)

USD 6,950 1,041,388円

レポートPDFを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

Printable PDF (Enterprise License)

USD 8,950 1,341,068円

レポートPDFの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.84円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

体外診断用酵素市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の体外診断用酵素市場規模は2030年までに30億5,000万米ドルに達すると予測されています。

同市場は2025～2030年にかけてCAGR 10.2％で成長すると予測されています。臨床疾患の正確かつ迅速な診断と治療は、最適な臨床結果を得るために不可欠です。注目すべき生体触媒特性により、酵素は幅広い疾患の診断に使用されています。

酵素バイオセンサの開発は、臨床診断における酵素の有用性を高めています。臨床診断における必要性にもかかわらず、バイオセンサの商業化と研究から臨床への移行はまだ低いです。しかし、研究開発努力の増加に伴い、乳酸、コレステロール、グルコースバイオセンサが診断用に製品化されています。

プロテアーゼは重要なシグナル伝達タンパク質であり、がん、神経疾患、炎症性疾患、心血管疾患など、いくつかの病理学的プロセスに不可欠です。ポリメラーゼとトランスクリプターゼ酵素は、予測期間中に最も速いCAGRを示すと予想されます。さらに、これらの酵素を提供する参入企業が多数存在することが、成長を促進すると予想されます。Kaneka Eurogentec S.A.、東洋紡株式会社、Sekisui Diagnostics, LLCなどの主要企業は、KOD DNA Polymerase、Taq DNA Polymerase、Tth DNA Polymerase、TTx DNA Polymeraseなど、幅広い種類のポリメラーゼを製造・販売しています。

2019年は感染症セグメントが市場を独占しました。世界のCOVID-19症例の急激な増加が、COVID-19診断用診断酵素の採用率を押し上げています。感染症診断のためのリアルタイムPCR、LAMP-PCR（Loop-mediated Isothermal Amplification-PCR）、マルチプレックスPCR、デジタルPCR技術による定性的と定量的分子アッセイの利用可能性の増加が、このセグメントにおける酵素の需要を促進しています。

酵素免疫組織化学（IHC）は、より優れたコントラスト比と、標的成分の検出のために複数のステインと使用できる手法の互換性により、組織学に好まれています。体外診断用医薬品（IVD）酵素は、組織検体や体液の分析のために、さまざまな最終用途で使用されています。1日に複数の分析を行う大規模ラボや、少数の検査を行う小規模クリニックなど、幅広いエンドユーザーが体外診断（IVD）用酵素を使用しています。

北米は2019年、顕著な地域市場として浮上しました。がん患者数の増加や生検サンプルの病理組織検査への酵素の採用は、同地域の市場成長を促進すると予想される他の要因の一部です。対象人口の多さ、医療インフラの改善、アンメット・クリニカル・ニーズの高さ、政府のイニシアチブの増加、先進的診断技術のための研究開発活動の増加は、最も速い成長率でアジア太平洋市場を牽引すると予測されています。

同市場の主要企業は、市場での存在感を高めるため、新製品の発売、買収、提携、パートナーシップ、地理的拡大などに取り組んでいます。例えば、2020年6月、Codexis, Inc.はAlphazyme LLCと高忠実度DNAポリメラーゼ、T7 RNAポリメラーゼ、逆転写酵素の製造と共同販売に関する提携契約を締結しました。

体外診断用酵素市場レポートハイライト

酵素別では、ポリメラーゼと転写酵素が、分子診断アッセイへの幅広い応用により、2024年に最大のシェアを占めました。
疾患別では、感染症セグメントが予測期間を通じて市場を独占すると予測されます。
技術別では、がん診断における組織学的アッセイの有用性と、さまざまながん種の罹患率の上昇により、組織学的アッセイセグメントが2024年に最大のシェアを占めました。
最終用途別では、病院と診断ラボが2024年の市場を独占しました。これらの施設では、入院患者の増加やがん患者の入院数の増加により、組織病理学や細胞病理学のための生検検体の流入が多いです。
北米は、Innovative Research、Bio-Rad Laboratories, Inc.、Rockland Immunochemicals, Inc.、MyBioSource.com、RayBIoTech, Inc.など、この地域にかなりの数の参入企業が存在するため、2024年に市場全体を支配しました。

地域別市場シェア分析、2024年と2030年
地域別市場ダッシュボード
世界地域市場のスナップショット
市場規模と予測動向分析、2018～2030年
北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- ノルウェー
- スウェーデン
- デンマーク
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- タイ
ラテンアメリカ
- ブラジル
- アルゼンチン
中東・アフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第9章競合情勢

主要市場参入企業による最近の動向と影響分析
企業/競合の分類
ベンダー情勢
- 主要企業の市場シェア分析、2024年
- Merck KGaA
- Codexis, Inc
- F. Hoffmann-La Roche Ltd
- Amano Enzymes Inc
- Advanced Enzymes Technologies Ltd.
- Biocatalysts Ltd
- Amicogen
- Dyadic International
- BBI Solutions
- Affymetrix

図表

List of Tables

Table 1 List of Abbreviation
Table 2 North America in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 3 North America in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 4 North America in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 5 North America in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 6 North America in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
Table 7 U.S. in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 8 U.S. in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 9 U.S. in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 10 U.S. in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 11 Canada in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 12 Canada in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 13 Canada in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 14 Canada in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 15 Mexico in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 16 Mexico in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 17 Mexico in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 18 Mexico in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 20 Europe in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 21 Europe in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 22 Europe in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 23 Europe in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
Table 24 Germany in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 25 Germany in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 26 Germany in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 27 Germany in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 28 UK in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 29 UK in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 30 UK in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 31 UK in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 32 France in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 33 France in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 34 France in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 35 France in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 36 Italy in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 37 Italy in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 38 Italy in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 39 Italy in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 40 Spain in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 41 Spain in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 42 Spain in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 43 Spain in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 44 Sweden in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 45 Sweden in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 46 Sweden in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 47 Sweden in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 48 Norway in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 49 Norway in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 50 Norway in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 51 Norway in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 52 Denmark in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 53 Denmark in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 54 Denmark in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 55 Denmark in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 57 Asia Pacific in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 58 Asia Pacific in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 59 Asia Pacific in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 60 Asia Pacific in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
Table 61 China in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 62 China in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 63 China in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 64 China in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 65 Japan in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 66 Japan in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 67 Japan in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 68 Japan in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 69 India in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 70 India in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 71 India in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 72 India in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 73 Australia in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 74 Australia in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 75 Australia in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 76 Australia in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 77 Thailand in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 78 Thailand in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 79 Thailand in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 80 Thailand in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 81 South Korea in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 82 South Korea in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 83 South Korea in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 84 South Korea in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 86 Latin America in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 87 Latin America in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 88 Latin America in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 89 Latin America in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
Table 90 Brazil in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 91 Brazil in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 92 Brazil in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 93 Brazil in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 94 Argentina in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 95 Argentina in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 96 Argentina in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 97 Argentina in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 98 Middle East and Africa in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 99 Middle East and Africa in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 100 Middle East and Africa in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 101 Middle East and Africa in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 102 Middle East and Africa in-vitro diagnostics enzymes market, by region, 2018 - 2030 (USD Million)
Table 103 South Africa in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 104 South Africa in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 105 South Africa in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 106 South Africa in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 111 UAE in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 112 UAE in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 113 UAE in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 114 UAE in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)
Table 115 Kuwait in-vitro diagnostics enzymes market, by enzymes, 2018 - 2030 (USD Million)
Table 116 Kuwait in-vitro diagnostics enzymes market, by disease, 2018 - 2030 (USD Million)
Table 117 Kuwait in-vitro diagnostics enzymes market, by technology, 2018 - 2030 (USD Million)
Table 118 Kuwait in-vitro diagnostics enzymes market, by end use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 In-vitro diagnostics enzymes: Market outlook
Fig. 9 In-vitro diagnostics enzymes: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 In-vitro diagnostics enzymes market driver impact
Fig. 15 In-vitro diagnostics enzymes market restraint impact
Fig. 16 In-vitro diagnostics enzymes market strategic initiatives analysis
Fig. 17 In-vitro diagnostics enzymes market: Enzyme movement analysis
Fig. 18 In-vitro diagnostics enzymes market: Enzyme outlook and key takeaways
Fig. 19 Proteases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Polymerase & transcriptase market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Ribonuclease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 In-vitro diagnostics enzymes market: Disease type movement analysis
Fig. 24 In-vitro diagnostics enzymes market: Disease type outlook and key takeaways
Fig. 25 Infectious disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Cardiology market estimates and forecasts, 2018 - 2030
Fig. 29 Nephrology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Autoimmune diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 In-vitro diagnostics enzymes market: Technology movement analysis
Fig. 33 In-vitro diagnostics enzymes market: Technology outlook and key takeaways
Fig. 34 Histology assays market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Molecular diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Clinical chemistry market estimates and forecasts, 2018 - 2030
Fig. 37 Others market estimates and forecasts, 2018 - 2030
Fig. 38 In-vitro diagnostics enzymes market: End use movement analysis
Fig. 39 In-vitro diagnostics enzymes market: End use outlook and key takeaways
Fig. 40 Pharma & biotech market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Hospital & diagnostic labs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Contract Research Organizations (CROs) market estimates and forecasts, 2018 - 2030
Fig. 43 Academic labs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Global in-vitro diagnostics enzymes market: Regional movement analysis
Fig. 45 Global in-vitro diagnostics enzymes market: Regional outlook and key takeaways
Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Product Code: GVR-4-68039-246-6

In-vitro Diagnostics Enzymes Market Growth & Trends:

The global in-vitro diagnostics enzymes market size is anticipated to reach USD 3.05 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.2% from 2025 to 2030. Accurate and rapid diagnosis and treatment of clinical disorders are essential for optimal clinical outcomes. Owing to the noteworthy biocatalytic properties, enzymes are used in the diagnosis of a wide range of diseases.

The development of enzyme biosensors has increased the enzyme utility in clinical diagnostics. Despite the necessity in clinical diagnosis, the commercialization and translation of biosensors from research to clinics are still low. However, with an increase in R&D efforts, lactate, cholesterol, and glucose biosensors have been commercialized for diagnostic use.

Proteases are important signaling proteins that are critical to a few pathological processes, including cancer, neurological, inflammatory, and cardiovascular disorders. Polymerase and transcriptase enzymes are expected to exhibit the fastest CAGR over the forecast period. In addition, the presence of a substantial number of players that offer these enzymes is expected to enhance the growth. Key players such as Kaneka Eurogentec S.A.; Toyobo Co., Ltd.; and Sekisui Diagnostics, LLC manufacture and distribute a wide range of polymerases, including KOD DNA Polymerase, Taq DNA Polymerase, Tth DNA Polymerase, and TTx DNA Polymerase.

The infectious disease segment dominated the market in 2019. An exponential rise in the COVID-19 cases globally drives the adoption rate of diagnostic enzymes for COVID-19 diagnosis. An increase in the availability of qualitative and quantitative molecular assays based on real-time PCR, Loop-mediated Isothermal Amplification- PCR (LAMP-PCR), multiplex PCR, and digital PCR technologies for the diagnosis of infectious diseases drives the demand for enzymes in this segment.

Enzymatic immunohistochemistry (IHC) is preferred for histology owing to a better contrast ratio and the method's compatibility for use with multiple stains for the detection of target components. IVD enzymes are employed in different end-use settings for the analysis of tissue specimens and bodily fluids. A wide range of end users including large laboratories that conduct multiple analyses in a day and smaller clinics that conduct a few tests use enzymes for in-vitro diagnostics (IVD).

North America emerged as a prominent regional market in 2019. A rise in the number of cancer cases and the adoption of enzymes for histopathology of biopsy samples are some of the other factors expected to propel market growth in the region. The presence of a large target population, improvements in healthcare infrastructure, high unmet clinical needs, increase in government initiatives, and rise in R&D activities for advanced diagnostic techniques are anticipated to drive the Asia Pacific market with the fastest growth rate.

The key players in the market are involved in novel product launches, acquisitions, collaborations, partnerships, and geographical expansions to reinforce their market presence. For instance, in June 2020, Codexis, Inc. signed a collaboration agreement with Alphazyme LLC for the manufacture and co-marketing of high-fidelity DNA polymerase, T7 RNA polymerase, and reverse transcriptase.

In-vitro Diagnostics Enzymes Market Report Highlights:

By enzyme type, polymerase and transcriptase enzymes held the largest share in 2024 owing to their wide applications in molecular diagnostic assays
Based on disease type, the infectious disease segment is expected to dominate the market throughout the forecast period
In terms of technology type, the histology assays segment held the largest share in 2024 owing to the utility of histology assays in cancer diagnostics, coupled with a rising incidence of different cancer types
By end use, hospital and diagnostic labs dominated the market in 2024. They witness a high inflow of biopsy specimens for histopathology and cytopathology because of an increase in hospitalization and rise in the number of hospital admissions for cancer patients
North America dominated the overall market in 2024 owing to the presence of a substantial number of players in this region including Innovative Research; Bio-Rad Laboratories, Inc.; Rockland Immunochemicals, Inc.; MyBioSource.com; and RayBiotech, Inc.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Enzyme
- 1.2.2. Disease
- 1.2.3. Technology
- 1.2.4. End Use
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Enzyme outlook
- 2.2.2. Disease outlook
- 2.2.3. End use outlook
- 2.2.4. Technology outlook
- 2.2.5. Regional outlook
2.3. Competitive Insights

Chapter 3. In-vitro Diagnostics Enzymes Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Increasing Prevalence of Chronic Diseases
  - 3.2.1.2. Advancements in Diagnostic Technologies
  - 3.2.1.3. Rising Demand for Personalized Medicine
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High Cost of Diagnostic Tests
  - 3.2.2.2. Lack of Awareness in Emerging Markets
3.3. In-vitro Diagnostics Enzymes Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. In-vitro Diagnostics Enzymes Market: Enzyme Estimates & Trend Analysis

4.1. Enzyme Market Share, 2024 & 2030
4.2. Segment Dashboard
4.3. Global In-vitro Diagnostics Enzymes Market by Enzyme Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Proteases
  - 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
- 4.4.2. Polymerase & Transcriptase
  - 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Ribonuclease
  - 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.4. Others
  - 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In-vitro Diagnostics Enzymes Market: Disease Estimates & Trend Analysis

5.1. Disease Market Share, 2024 & 2030
5.2. Segment Dashboard
5.3. Global In-vitro Diagnostics Enzymes Market by Disease Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Infectious Disease
  - 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  - 5.4.1.2. COVID -19 Testing
    - 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 5.4.1.3. Hepatitis
    - 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 5.4.1.4. HIV
    - 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 5.4.1.5. Others
    - 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Diabetes
  - 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Oncology
  - 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Cardiology
  - 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.5. Nephrology
  - 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.6. Autoimmune Diseases
  - 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.7. Others
  - 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In-vitro Diagnostics Enzymes Market: Technology Estimates & Trend Analysis

6.1. Technology Market Share, 2024 & 2030
6.2. Segment Dashboard
6.3. Global In-vitro Diagnostics Enzymes Market by Technology Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.4.1. Histology Assays
  - 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
- 6.4.2. Molecular Diagnostics
  - 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 6.4.2.2. PCR Assays
    - 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 6.4.2.3. NGS Assays
    - 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 6.4.2.4. Others
    - 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. Clinical Chemistry
  - 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In-vitro Diagnostics Enzymes Market: End Use Estimates & Trend Analysis

7.1. End Use Market Share, 2024 & 2030
7.2. Segment Dashboard
7.3. Global In-vitro Diagnostics Enzymes Market by End Use Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.4.1. Pharma & Biotech
  - 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
- 7.4.2. Hospital & Diagnostic Labs
  - 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. Academic Labs
  - 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. In-vitro Diagnostics Enzymes Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
- 8.5.1. U.S.
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Regulatory framework/ reimbursement structure
  - 8.5.1.3. Competitive scenario
  - 8.5.1.4. Target disease prevalence
  - 8.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. Canada
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. Target disease prevalence
  - 8.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. Mexico
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Regulatory framework/ reimbursement structure
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. Target disease prevalence
  - 8.5.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million
8.6. Europe
- 8.6.1. UK
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Regulatory framework/ reimbursement structure
  - 8.6.1.3. Competitive scenario
  - 8.6.1.4. Target disease prevalence
  - 8.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Germany
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Target disease prevalence
  - 8.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.3. France
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Regulatory framework/ reimbursement structure
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. Target disease prevalence
  - 8.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.4. Italy
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Regulatory framework/ reimbursement structure
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. Target disease prevalence
  - 8.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.5. Spain
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Regulatory framework/ reimbursement structure
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. Target disease prevalence
  - 8.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.6. Norway
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Regulatory framework/ reimbursement structure
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. Target disease prevalence
  - 8.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.7. Sweden
  - 8.6.7.1. Key country dynamics
  - 8.6.7.2. Regulatory framework/ reimbursement structure
  - 8.6.7.3. Competitive scenario
  - 8.6.7.4. Target disease prevalence
  - 8.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.8. Denmark
  - 8.6.8.1. Key country dynamics
  - 8.6.8.2. Regulatory framework/ reimbursement structure
  - 8.6.8.3. Competitive scenario
  - 8.6.8.4. Target disease prevalence
  - 8.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Asia Pacific
- 8.7.1. Japan
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Regulatory framework/ reimbursement structure
  - 8.7.1.3. Competitive scenario
  - 8.7.1.4. Target disease prevalence
  - 8.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. China
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. Target disease prevalence
  - 8.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. India
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Regulatory framework/ reimbursement structure
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. Target disease prevalence
  - 8.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.4. Australia
  - 8.7.4.1. Key country dynamics
  - 8.7.4.2. Regulatory framework/ reimbursement structure
  - 8.7.4.3. Competitive scenario
  - 8.7.4.4. Target disease prevalence
  - 8.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.5. South Korea
  - 8.7.5.1. Key country dynamics
  - 8.7.5.2. Regulatory framework/ reimbursement structure
  - 8.7.5.3. Competitive scenario
  - 8.7.5.4. Target disease prevalence
  - 8.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.6. Thailand
  - 8.7.6.1. Key country dynamics
  - 8.7.6.2. Regulatory framework/ reimbursement structure
  - 8.7.6.3. Competitive scenario
  - 8.7.6.4. Target disease prevalence
  - 8.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Latin America
- 8.8.1. Brazil
  - 8.8.1.1. Key country dynamics
  - 8.8.1.2. Regulatory framework/ reimbursement structure
  - 8.8.1.3. Competitive scenario
  - 8.8.1.4. Target disease prevalence
  - 8.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  - 8.8.1.6. )
- 8.8.2. Argentina
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Regulatory framework/ reimbursement structure
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. Target disease prevalence
  - 8.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.9. MEA
- 8.9.1. South Africa
  - 8.9.1.1. Key country dynamics
  - 8.9.1.2. Regulatory framework/ reimbursement structure
  - 8.9.1.3. Competitive scenario
  - 8.9.1.4. Target disease prevalence
  - 8.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.2. Saudi Arabia
  - 8.9.2.1. Key country dynamics
  - 8.9.2.2. Regulatory framework/ reimbursement structure
  - 8.9.2.3. Competitive scenario
  - 8.9.2.4. Target disease prevalence
  - 8.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.3. UAE
  - 8.9.3.1. Key country dynamics
  - 8.9.3.2. Regulatory framework/ reimbursement structure
  - 8.9.3.3. Competitive scenario
  - 8.9.3.4. Target disease prevalence
  - 8.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.4. Kuwait
  - 8.9.4.1. Key country dynamics
  - 8.9.4.2. Regulatory framework/ reimbursement structure
  - 8.9.4.3. Competitive scenario
  - 8.9.4.4. Target disease prevalence
  - 8.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
- 9.3.1. Key company market share analysis, 2024
- 9.3.2. Merck KGaA
  - 9.3.2.1. Company overview
  - 9.3.2.2. Financial performance
  - 9.3.2.3. Product benchmarking
  - 9.3.2.4. Strategic initiatives
- 9.3.3. Codexis, Inc
  - 9.3.3.1. Company overview
  - 9.3.3.2. Financial performance
  - 9.3.3.3. Product benchmarking
  - 9.3.3.4. Strategic initiatives
- 9.3.4. F. Hoffmann-La Roche Ltd
  - 9.3.4.1. Company overview
  - 9.3.4.2. Financial performance
  - 9.3.4.3. Product benchmarking
  - 9.3.4.4. Strategic initiatives
- 9.3.5. Amano Enzymes Inc
  - 9.3.5.1. Company overview
  - 9.3.5.2. Financial performance
  - 9.3.5.3. Product benchmarking
  - 9.3.5.4. Strategic initiatives
- 9.3.6. Advanced Enzymes Technologies Ltd.
  - 9.3.6.1. Company overview
  - 9.3.6.2. Financial performance
  - 9.3.6.3. Product benchmarking
  - 9.3.6.4. Strategic initiatives
- 9.3.7. Biocatalysts Ltd
  - 9.3.7.1. Company overview
  - 9.3.7.2. Financial performance
  - 9.3.7.3. Product benchmarking
  - 9.3.7.4. Strategic initiatives
- 9.3.8. Amicogen
  - 9.3.8.1. Company overview
  - 9.3.8.2. Financial performance
  - 9.3.8.3. Product benchmarking
  - 9.3.8.4. Strategic initiatives
- 9.3.9. Dyadic International
  - 9.3.9.1. Company overview
  - 9.3.9.2. Financial performance
  - 9.3.9.3. Product benchmarking
  - 9.3.9.4. Strategic initiatives
- 9.3.10. BBI Solutions
  - 9.3.10.1. Company overview
  - 9.3.10.2. Financial performance
  - 9.3.10.3. Product benchmarking
  - 9.3.10.4. Strategic initiatives
- 9.3.11. Affymetrix
  - 9.3.11.1. Company overview
  - 9.3.11.2. Financial performance
  - 9.3.11.3. Product benchmarking
  - 9.3.11.4. Strategic initiatives

体外診断用酵素の市場規模、シェア、動向分析レポート：酵素別、疾患別、技術別、最終用途別、地域別、セグメント別予測、2025年～2030年

In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme (Polymerase & Transcriptase, Proteases), By Disease (Infectious Disease, Diabetes), By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030

体外診断用酵素市場の成長と動向

体外診断用酵素市場レポートハイライト

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章体外診断用酵素市場の変数、動向、範囲

第4章体外診断用酵素市場：酵素、推定・動向分析

第5章体外診断用酵素市場：疾患推定・動向分析

第6章体外診断用酵素市場：技術別、推定・動向分析

第7章体外診断用酵素市場：最終用途別、推定・動向分析

第8章体外診断用酵素市場：地域別、推定・動向分析

第9章競合情勢

List of Tables

List of Figures

In-vitro Diagnostics Enzymes Market Growth & Trends:

In-vitro Diagnostics Enzymes Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. In-vitro Diagnostics Enzymes Market Variables, Trends & Scope

Chapter 4. In-vitro Diagnostics Enzymes Market: Enzyme Estimates & Trend Analysis

Chapter 5. In-vitro Diagnostics Enzymes Market: Disease Estimates & Trend Analysis

Chapter 6. In-vitro Diagnostics Enzymes Market: Technology Estimates & Trend Analysis

Chapter 7. In-vitro Diagnostics Enzymes Market: End Use Estimates & Trend Analysis

Chapter 8. In-vitro Diagnostics Enzymes Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

体外診断用酵素の市場規模、シェア、動向分析レポート：酵素別、疾患別、技術別、最終用途別、地域別、セグメント別予測、2025年～2030年

In-vitro Diagnostics Enzymes Market Size, Share & Trends Analysis Report By Enzyme (Polymerase & Transcriptase, Proteases), By Disease (Infectious Disease, Diabetes), By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2030

体外診断用酵素市場の成長と動向

体外診断用酵素市場レポートハイライト

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 体外診断用酵素市場の変数、動向、範囲

第4章 体外診断用酵素市場： 酵素、推定・動向分析

第5章 体外診断用酵素市場：疾患推定・動向分析

第6章 体外診断用酵素市場：技術別、推定・動向分析

第7章 体外診断用酵素市場：最終用途別、推定・動向分析

第8章 体外診断用酵素市場：地域別、推定・動向分析

第9章 競合情勢

List of Tables

List of Figures

In-vitro Diagnostics Enzymes Market Growth & Trends:

In-vitro Diagnostics Enzymes Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. In-vitro Diagnostics Enzymes Market Variables, Trends & Scope

Chapter 4. In-vitro Diagnostics Enzymes Market: Enzyme Estimates & Trend Analysis

Chapter 5. In-vitro Diagnostics Enzymes Market: Disease Estimates & Trend Analysis

Chapter 6. In-vitro Diagnostics Enzymes Market: Technology Estimates & Trend Analysis

Chapter 7. In-vitro Diagnostics Enzymes Market: End Use Estimates & Trend Analysis

Chapter 8. In-vitro Diagnostics Enzymes Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章体外診断用酵素市場の変数、動向、範囲

第4章体外診断用酵素市場：酵素、推定・動向分析

第5章体外診断用酵素市場：疾患推定・動向分析

第6章体外診断用酵素市場：技術別、推定・動向分析

第7章体外診断用酵素市場：最終用途別、推定・動向分析

第8章体外診断用酵素市場：地域別、推定・動向分析

第9章競合情勢